摘要
目的探讨新辅助化疗对浸润性膀胱癌预后的影响。方法通过Medline、中国生物医学数据库检索国内外已发表的相关文献。选择试验组为新辅助化疗+手术或放疗,对照组为单独手术或放疗的浸润性膀胱癌临床随机对照研究(RCT),提取资料后对5年生存率进行Meta分析。结果从1991￣2003年,有10项研究入选,新辅助治疗组1392人,单纯手术组1382人,分析结果显示新辅助治疗组与单纯手术组比较,死亡风险优势比0.79(95%CI0.67￣0.94),P=0.006。结论新辅助化疗适用于浸润性膀胱癌的治疗,可改善预后。
[Objective] To detect the effect of neoadjuvant chemotherapy on the prognosis of the patients with museular-invasive bladder cancer by Mate-analysis. [Methods] To search all RCT on neoadjuvant chemotherapy for museular-invasive bladder cancer in MEDLINE and CNKI database. Meta-Analysis was performed by collecting information in accordance with inclusion and exclusion criteria from all papers available. 5-year＇s survival was compared between a control group of patients treated with surgery or radiotherapy alone and a group of patients treated with radical cystectomy or radiotherapy plus neoadjuvant chemotherapy. [Results] 10 trials entered the Meta-analysis from 1991 to 2003. A total of 2801 （27 exclusion） were included in analysis （1392 in study group and 1382 in control group）. There is a significant difference in survival between study group （neoadjuvant chemotherapy plus surgery group） and control group （surgery group）. [odds ratio （OR） 0. 79, 95%CI 0.67 to 0.94, P =0.006]. [Conclusion] The result provides the available evidence in support of neoadjuvant chemotherapy for patients with invasive muscular bladder cancer.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2007年第1期99-102,共4页
China Journal of Modern Medicine
关键词
新辅助化疗
浸润性膀胱癌
手术前化疗
neoadjuvant chemotherapy
invasive muscular bladder cancer
, preoperative chemotherapy
